NDA Submission Update for Ponatinib for Chronic Myeloid Leukemia and Philadelphia-positive Acute Lymphoblastic Leukemia
ARIAD Pharmaceuticals announced it has completed the rolling submission of the New Drug Application (NDA) for ponatinib to the FDA, seeking marketing approval in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
ARIAD provided the FDA with remaining chemistry, manufacturing, and controls (CMC) data. The Company has requested accelerated approval and a priority review of the ponatinib application by the FDA.
Ponatinib is an investigational BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT, and the members of the FGFR and PDGFR families of kinases. The primary target for ponatinib is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment with existing tyrosine kinase inhibitors, including the T315I mutation for which no effective therapy currently exists.For more information call (877) 621-2302 or visit www.ariad.com.